Suggested Searches

photo of Monica Hagan Vetter
859-278-5671

Monica Hagan Vetter, MD

Gynecologic Oncology
Gender: Female
4.9 of 5 (112 Ratings)
Accepting New Patients

Clinical Focus

Gynecologic Cancers, Laser Surgery, Ovarian Cancer and Ovarian Masses, Radical Pelvic Surgery, Robotic Gynecologic Cancer Surgery, Trophoblastic Disease, Uterine Cancer, Uterine Masses

Practice Locations

A:
Baptist Health Medical Group Gynecologic Oncology
1700 Nicholasville Road, Suite 1100
Lexington, KY 40503
859-278-5671 859-278-5978

Education

Medical School

University of Louisville School of Medicine

Residency

Ohio State University Hospital

Residency

Ohio State University

Fellowship

Ohio State University

Board Certifications

Gynecologic Oncology

American Board of Obstetrics and Gynecology

Hospital Affiliations

  • Baptist Health Lexington

Philosophy of Care

Baptist Health Medical Group is a comprehensive, multispecialty network of physicians and advanced practice clinicians. Our providers are committed to providing compassionate, patient-centered care and strive to treat our patients the way we would want to be treated, every time, at every Baptist Health location.

Reviews

Patient Experience Ratings

The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Overall Rating
4.9 out of 5 (112 Ratings)
Review Categories
Patient Comments

Research

  • CIRB-21-0040

    CCOO8: A study to compare two surgical procedures in women with BRCA1 mutations to assess reduced risk of ovarian cancer

    Trial Details
  • CIRB220046

    This phase II/III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin HylectaTM) or pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial serous carcinoma or carcinosarcoma. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab or pertuzumab attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Hyaluronidase is an endoglycosidase. It helps to keep pertuzumab and trastuzumab in the body longer, so that these medications will have a greater effect. Hyaluronidase also allows trastuzumab and trastuzumab/pertuzumab to be given by injection under the skin and shortens their administration time compared to trastuzumab or pertuzumab alone. Paclitaxel is a taxane and in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Giving Herceptin Hylecta or Phesgo in combination with paclitaxel and carboplatin may shrink the tumor and prevent the cancer from coming back in patients with HER2 positive endometrial serous carcinoma or carcinosarcoma.

    Learn more at ClinicalTrials.gov.

    Trial Details
  • WIRB-21-0068

    GOG-3039: A Phase II Study of Abemaciclib in Combination with Letrozole in Advanced, Recurrent or Metastatic Endometrioid Endometrial Cancer

    Trial Details